Organization
Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America
6 abstracts
Abstract
Anti-tnf treatments for women with chronic inflammatory diseases: comparing attitudes and perceptions of physicians in europe and the usOrg: Università degli Studi di Brescia, Brescia, Italy, Botnar Research Centre, Oxford, United Kingdom, Rheumatology & Hiller Research Unit, University Hospital, Düsseldorf, Germany, UCB Pharma, Brussels, Belgium, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America,
Abstract
ANIFROLUMAB REDUCES DISEASE ACTIVITY IN MULTIPLE ORGAN DOMAINS IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Org: Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America, Northwell Health, Great Neck, NY, United States of America, MedImmune, Gaithersburg, United States,
Abstract
ASSOCIATION OF VECTRA™ DA, A NOVEL MULTI-BIOMARKER TEST OF RHEUMATOID ARTHRITIS DISEASE ACTIVITY, WITH DAS28CRP Org: Crescendo Bioscience, South San Francisco, CA, United States, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America, Long Island Rheumatology Associates, Melville, NY, Biogen,
Abstract
A LUPUS FLARE RISK INDEX INFORMED BY SELECT ADAPTIVE AND TNF SUPERFAMILY IMMUNE MEDIATORS: VALIDATION IN A CONFIRMATORY COHORTOrg: Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America, Progentec Diagnostics, Inc., Oklahoma City, OK, United States of America, Mayo Clinic, Rochester, MN, United States of America, Medical University of South Carolina, Charleston, SC, United States of America, NYU Grossman School of Medicine, New York, NY, United States of America,
Abstract
AN OPEN-LABEL STUDY OF THE SAFETY OF RITUXIMAB (RTX) IN COMBINATION WITH OTHER BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) Org: Dartmouth Hitchcock Medical Center, Lebanon, Swedish Rheumatology Associates, Seattle, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America, Genentech, South San Francisco, United States,
Abstract
ANIFROLUMAB, AN ANTI-INTERFERON-ALPHA RECEPTOR MONOCLONAL ANTIBODY, IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) Org: Northwell Health, Great Neck, NY, United States of America, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States of America, Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, United States, Graham Hughes Lupus Research Laboratory Division of Women's Health, London, United Kingdom, UCSD School of Medicine, La Jolla,